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ABSTRACT A 49-year-old man with recalcitrant mechanobullous 
epidermolysis bullosa acquisita (EBA) with significant esophageal 
involvement was treated with rituximab. EBA is a chronic autoim-
mune subepidermal bullous disease. It is characterized by skin fragil-
ity and scarring caused by circulating and tissue bound antibodies 
to type VII collagen. EBA is often unresponsive or poorly responsive 
to conventional immunosuppressive therapies such as corticoste-
roids, methotrexate, and cyclosporine. The burden of long-term 
use of immunosuppressants also limits their use in the treatment 
of chronic autoimmune diseases such as EBA. Since a validated and 
objective way of measuring disease activity in patients with EBA 
has not been described, we used the Epidermolysis Bullosa Disease 
Activity Scoring Index (EBDASI), for hereditary EB, as a surrogate 
to measure disease severity and activity in our patient with EBA. 
After three courses of rituximab over three years, our patient has 
achieved near complete clinical remission from disease activity. The 
patient’s response suggests that treatment with rituximab may be a 
valuable treatment regimen for severe mechanobullous EBA, which 
is demonstrated by paralleled declines in objective disease activity 
scores, the EBDASI. This is in line with recently observed beneficial 
effects of rituximab in the management of EBA.
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INTRODUCTION
In 1904, the term epidermolysis bullosa acquisita 
(EBA) was used for those who had developed fea-
tures and symptoms similar to hereditary dystrophic 
EB later in life. This was due to the clinical similarities 
and overlap of features. EBA is characterized by skin 
fragility and sub-epidermal bullous formation with 
light trauma on both mucosal and cutaneous surfac-
es. Similar to dystrophic EB, the clinical presentation 
and severity of disease can vary significantly between 
patients with EBA. Unlike hereditary EB, EBA is a rare 
acquired autoimmune bullous disease.
EBA is caused by circulating IgG autoantibodies 
against the type VII collagen found in anchoring fi-
brils that are expressed at the basement membrane 
zone of stratified squamous epithelia. This loss of skin 
cell adhesion causes severe subepidermal blistering 
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that presents as a chronic and relapsing disease that 
can lead to significant comorbidities and impact on 
patient quality of life. Conventional immunosuppres-
sive therapy is often minimally effective and, due to 
its rarity, a validated score to measure disease activity 
does not exist. 
The EBDASI was validated to measure the disease 
activity and damage in patients with genetic epider-
molysis bullosa. Due to the clinical overlap between 
patients with EBA and hereditary dystrophic EB, we 
have appropriated the use of the EBDASI in our pa-
tient with EBA. 
We present a case where rituximab was used to 
treat recalcitrant EBA with significant esophageal in-
volvement. Our patient experienced almost complete 
clinical remission. The disappearance of mucocutane-
ous erosions was paralleled by the decline in EBDASI 
activity scores, the need for esophageal dilatations, 
and an improvement in quality of life measures and 
weight.
 CASE REPORT
A 49-year-old man was diagnosed with EBA in 
1994. His diagnosis was confirmed with a skin bi-
opsy, direct and indirect immunofluorescence, and 
immunoblotting (1). Previous treatments included 
prednisone up to 200 mg/day, azathioprine, cyclo-
sporine, dapsone, tetracyclines, photophoresis, and 
plasmapheresis. He was referred to our dermatology 
clinic in 2004 with a history of spontaneous blisters 
and extreme skin fragility especially on trauma-prone 
sites including the hands, feet, elbows, and knees. He 
suffered from the effects of extensive cutaneous and 
mucosal ulceration with significant involvement of 
the esophagus and alimentary tract. He experienced 
pain on a daily basis. He could no longer work, was 
unable to tolerate solid food, and became socially 
isolated.
An examination of his skin noted multiple large 
patches of erosions on his buttocks, legs, shoulders, 
head and hands, and milia and dystrophy of his nails 
(Figure 1). 
 A history of hemoptysis and progressive dys-
phagia was investigated with a barium swallow. This 
demonstrated esophageal rings and pharyngeal and 
cervical webs. He was referred to a gastroenterologist, 
and severe narrowing of the cricopharyngeus was 
observed on endoscopic examination (Figure 1). 
As his esophageal symptoms progressively wors-
ened over time, he required an increasing number of 
dilatations. Between November 2006 and November 
2012, prior to receiving rituximab therapy, he required 
ten esophageal dilatations to manage his dysphagia. 
These were each performed with the prophylactic 
corticosteroid cover (prednisone 1 mg/kg). Despite 
the dilatations, his dysphagia symptoms would pro-
gressively deteriorate within months of each dilata-
tion. He was no longer able to tolerate solid food and 
by 2012 he weighed only 55 kg.   
 He had developed significant treatment-related 
comorbidities from long term systemic corticosteroid 
therapy. Skin atrophy, striae, poor wound healing, hy-
pertension, and a bone mineral density scan demon-
strated established osteoporosis. Despite aggressive 
therapy, he was only ever able to achieve poor dis-
ease control. After decades of only temporizing treat-
ment, he was reluctant to try any new therapies. 
Figure 1. Response of epidermolysis bullosa acquisita (EBA) 
cutaneous manifestations before and after rituximab. a) 
Hands before; b) Hands after; c) Endoscopic view of aryte-
noid cartilages before; d) Arytenoid cartilages after.
Figure 2. Epidermolysis Bullosa Disease Activity Scoring 
Index (EBDASI) score over time demonstrating reduction in 
EBDASI activity with each rituximab treatment (red arrows) 
and weight (kg).
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With counselling and support he was persuaded 
to undergo his first course of rituximab, 375 mg/m2/
week for four weeks in November 2012. Within the 
first month of the rituximab infusion there was pro-
gressive improvement of his clinical symptoms. An 
objective improvement in his EBDASI score was doc-
umented three months after his first treatment. 
Over the following year there was a slow return 
of his symptoms and he received a second course of 
rituximab in April 2014. In June of 2015 he received 
his third course of rituximab, given as 1000 mg doses 
two weeks apart (Figure 2). 
There was a discernible reduction in the number 
of esophageal dilatations our patient had required 
after commencing rituximab therapy. Within the ini-
tial 30 months after his first dose of rituximab from 
November 2012 to March 2016 he required eleven 
dilatations. Since April 2016 he has not needed any 
further esophageal treatments. Furthermore, since 
receiving rituximab he has been able to tolerate a 
solid diet with reduced discomfort and has subse-
quently gained 13 kg in weight, back to his pre-mor-
bid weight of 68 kg.
To date, the disease continues to be manage-
able. More importantly he has gained a significant 
improvement in his quality of life demonstrated by 
a reduction in Autoimmune Bullous Quality of Life 
(ABQOL) score that has been reduced from 39 to 7 
and Treatment Autoimmune Quality of Life (TABQOL) 
scores, 26 to 14. He no longer requires special diet 
modifications and he has been able to return back to 
the workforce.
DISCUSSION 
Epidermolysis bullosa acquisita (EBA) is very rare, 
autoimmune sub-epidermal bullous disease. It is char-
acterized by skin fragility and scarring caused by an-
tibodies to type VII collagen. This is the main collagen 
found in the anchoring fibrils that bind the epider-
mis to the dermis at the dermal epidermal junction. 
Damage to the anchoring fibrils causes potentially 
severe subepidermal blistering. There are five clini-
cal variants of EBA: the traditional mechanobullous 
type, inflammatory bullous type, the MMP-like EBA, 
IgA EBA, and Brunsting Perry like (2). His phenotype 
was unusual in being classical and extensive in his 
skin but also severe in the esophagus. The severity of 
disease can vary across a wide spectrum, from some 
patients only experiencing skin fragility to those who 
suffer significant epithelial and mucosal involvement, 
including esophageal and anorectal disease. Esopha-
geal involvement can lead to stricture formation and 
significant morbidity. 
As the name suggests, EBA is an acquired disease 
that has characteristics similar to that of the genetic 
dystrophic epidermolysis bullosa. However, unlike he-
reditary EB, a validated disease activity scoring system 
does not exist for EBA. In 2012, the EBDASI was validat-
ed to measure the disease activity and damage in pa-
tients with the genetic disease epidermolysis bullosa 
(EB). It scores disease activity and damage separately. 
It measures skin, mucous membrane, and hair and 
nail involvement (3). This scoring tool has been valu-
able in objectively measuring and monitoring disease 
progression and treatment response in patients with 
genetic EB. Due to the clinical overlap between dys-
trophic EB and EBA, we have used it in a patient with 
EBA. We also used the Autoimmune Bullous Quality 
of Life (ABQOL) and Treatment Autoimmune Bullous 
Quality of Life (TABQOL) to measure the effect of dis-
ease and treatment on the quality of life (QOL) in our 
patient (4).
EBA often fails to respond to conventional therapy 
or only provides short term improvement. Conven-
tional therapy is usually considered to be high-dose 
systemic corticosteroids in conjunction with adjuvant 
immunosuppressive therapy. With the management 
of esophageal involvement several reports suggest 
a variety of treatments, varying from conservative 
management, dilation with prophylactic prednisone 
therapy, and endoscopic treatment with thermoplas-
tic dilators and intra-lesional steroid injections (5-7). 
Esophageal dilatations with prednisone or dexameth-
sone cover provided temporary relief for our patient 
and he continued to require an increasing number of 
dilatations to maintain their effect.
The burden of adverse effects due to the long-
term use of systemic corticosteroids limits their use in 
a chronic and relapsing disease such as EBA. In recent 
times, rituximab has been described as presenting an 
alternative modality for patients with EBA that is unre-
sponsive to conventional treatment or limited by the 
adverse effect profile (8-13). B-cells in autoimmune 
diseases such as EBA play a role in antigen presenta-
tion, regulation of inflammation, and production of 
autoantibodies. Rituximab is a humanized monoclonal 
antibody which causes B-cell depletion by binding to 
the CD20 molecule expressed on these cells. Our pa-
tient initially received the more often used lymphoma 
dosing regimen (375 mg/m2 weekly for four weeks) for 
the first two doses. He then received the rheumatoid 
arthritis regimen (1000 mg doses given two weeks 
apart) for the third dose. This is based on the idea that 
autoimmune diseases such as EBA have a lower B-cell 
burden than lymphoma and therefore should not re-
quire such high doses. However, the optimal dosing 
for rituximab in EBA has not been established.
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With the introduction of rituximab therapy, the pa-
tient has not required any further dilations since April 
2016. The reduction in his EBDASI activity scores par-
allels this clinical improvement. There was a marked 
reduction in his disease severity scores within three 
months of his initial dose of rituximab. Over time, 
there was progressive return of his symptoms and 
he consequently received a second dose a year later. 
This was followed with further improvement of his 
symptoms that was consolidated with his last dose of 
rituximab in 2016.
CONClUSION
The EBDASI is a useful surrogate scoring tool to 
measure the disease severity, damage, and activity in 
patients with EBA. This tool was used to demonstrate 
the response to rituximab in our patients with recal-
citrant EBA. Rituximab, used as a sole agent, achieved 
near complete remission in a patient with severe, re-
calcitrant EBA resulting in considerable improvement 
in QOL and weight, with the use of the EBDASI to doc-
ument the reduction in disease activity in a patient 
with EBA. 
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